OUTLOOK THERAPEUTICS, INC.

Analyst Reco. Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.43 ^USD	+2.93%		+3.18%	+6.98%

Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI
Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	Mar. 27	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	Feb. 15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	Feb. 15	MT
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	Jan. 25	MT
Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57	Jan. 25	MT
Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target	Dec. 27	MT
Chardan Downgrades Outlook Therapeutics to Neutral From Buy	23-08-31	MT
HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1	23-08-31	MT
Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy	23-08-30	MT
Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50	23-08-30	MT
BTIG Downgrades Outlook Therapeutics to Neutral From Buy	23-08-30	MT
Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target	23-07-13	MT
Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target	23-04-03	MT
Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target	23-02-06	MT
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating	23-01-06	MT
BTIG Starts Outlook Therapeutics at Buy With $7 Price Target	22-10-31	MT
Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target	22-09-13	MT
Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating	21-12-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer